.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Army
AstraZeneca
Chubb
Boehringer Ingelheim
QuintilesIMS
Cantor Fitzgerald
Argus Health
Baxter
US Department of Justice
Harvard Business School

Generated: September 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Method for treating mycosis using imidazolylacetonitrile derivatives
Abstract:R-(+)-(E)-[4-(2-Chlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonit rile, R-(-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylace tonitrile, and pharmaceutically acceptable salts thereof which can be used as a pharmaceutical agent are disclosed. A process for producing them and a method for treating mycoses using them are also disclosed.
Inventor(s): Kodama; Hiroki (Osaka, JP), Niwano; Yoshimi (Osaka, JP), Kanai; Kazuo (Osaka, JP), Yoshida; Masanori (Wakayama, JP)
Assignee: Nihon Nohyaku Co., Ltd. (Tokyo, JP)
Application Number:08/981,420
Patent Claims: 1. R-(-)-(E)-[ 4-(2,4-Dichlorophenyl)-1,3-dithilan-2-ylidene]-1-imidazolylacetonitrile or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising as an active ingredient R-(-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylace tonitrile, or a pharmaceutically acceptable salt thereof; together with a pharmaceutically acceptable carrier or diluent.

3. A process for producing R-(-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylace tonitrile represented by formula (B): ##STR16## which comprises reacting an optically active glycol derivative represented by formula (II) with a dithiolate salt represented by formula (III): ##STR17## wherein X.sub.1 and X.sub.2 are the same or different and each represents a methanesulfonyloxy group, a benzenesulfonyloxy group, a p-toluenesulfonyloxy group, or a halogen atom: ##STR18## wherein M represents an alkali metal atom.

4. A method for preventing or treating mycosis which comprises administrating to a human or animal in need of such prevention or treatment, a pharmaceutically effective amount of R-(-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylace tonitrile, or a pharmaceutical acceptable salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
AstraZeneca
Boehringer Ingelheim
Queensland Health
Baxter
Julphar
Healthtrust
Deloitte
Accenture
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot